Limitations
Short-term follow-up and small sample size were among the barriers that limited the present study. Hence, to increase the accuracy rate of the findings in the detection of the postpartum hemorrhages, other researchers are recommended not only to assess the severity or volume of the hemorrhage but also, they are also encouraged to analyze the mean number of days with hemorrhage throughout the intervention.
Conclusion
Outpatient treatment in patients with miscarriage can be carried out by the administration of oxytocin and methylergometrine in combination with misoprostol. This form of medical therapy has demonstrated positive impacts on the expulsion of retained products of conception (RPOC) during the first trimester and was more cost-effective compared to surgical and hospitalization approaches. Moreover, outpatient treatments in cases of medical abortion and avoidance of hospitalization are advantageous, especially during the Covid-19 pandemic. Not only it preserves the medical care resources, service management, and effectively improve women’s status of physical and mental health, but it is also more convenient for the patients to manage the pain at ease as they receive psychological support from their families at home. Besides, these patients with outpatient treatment often find the opportunity to handle housework affairs and can also meet other children’s needs at home. Thereby, patients’ tendency toward outpatient treatments motivated us to apply certain therapeutic methods to manage intrauterine fetal death during the first trimester. We believe that this medical therapy is more cost-effective and it is a safer therapeutic approach for the patients compared to surgical methods. Thus, we suggest all medical experts continue with outpatient treatment.
Declarations
Ethical approval of the study
Written inform consent was obtained from the patients in our study. The purpose of this research was completely explained to the patient and was assured that their information will be kept confidential by the researcher. This research was approved by the ethical committee of Jahrom University of Medical Sciences issued with code No.: IR.JUMS.REC.1396.143, and it was further registered in the Iranian registry of clinical trials with code ID of IRCT20200122046221N1.
Consent for publication
Consent was obtained from the patients regarding the publication of this study.
Availability of data and materials
SPSS data of the participant can be requested from the authors. Please write to the corresponding author if you are interested in such data.
Competing interests
The authors declare that they have no competing interests.
Funding
No financial support was received for this study.
Acknowledgments
We would like to express our sincere gratitude to the Clinical Research Development Unit of Peymanieh Educational and Research and Therapeutic Center affiliated to Jahrom University of Medical Sciences for providing suitable environmental facilities and research requirements.
Authors contribution
AR designed the study. AM and ZZ collected the data, NT drafted the manuscript and RS revised and edited the manuscript. All authors proof read and approved the final version of the manuscript.
References
1. Obstetricians, A.C.o. and Gynecologists, ACOG Committee Opinion No. 427: Misoprostol for postabortion care. Obstet. Gynecol, 2009. 113(2 Pt 1): p. 465.
2. Say, L., et al., Global causes of maternal death: a WHO systematic analysis. Lancet Glob. Health, 2014. 2(6): p. e323-e333.
3. Jones, R.K. and J. Jerman, Abortion incidence and service availability in the United States, 2014. Perspect. Sex. Reprod. Health, 2017. 49(1): p. 17-27.
4. Hooker, A.B., et al., Long-term complications and reproductive outcome after the management of retained products of conception: a systematic review. Fertil. Steril., 2016. 105(1): p. 156-164. e2.
5. Ambusaidi, Q. and A. Zutshi, Effectiveness of Misoprostol for Induction of First-Trimester Miscarriages: Experience at a single tertiary care centre in Oman. Sultan Qaboos Univ. Med. J, 2015. 15(4): p. e534.
6. Raymond, E.G., et al., Mortality of induced abortion, other outpatient surgical procedures and common activities in the United States. Contraception, 2014. 90(5): p. 476-479.
7. Thiebaut, M., et al., Retrospective assessment of the influence of gestational age on the first trimester medical abortion efficiency. Rev Med Liege, 2017. 72(4): p. 193-198.
8. Ibiyemi, K.F., A.I. Munir’deen, and K.T. Adesina, Randomised Trial of Oral Misoprostol Versus Manual Vacuum Aspiration for the Treatment of Incomplete Abortion at a Nigerian Tertiary Hospital. Sultan Qaboos Univ. Med. J, 2019. 19(1): p. e38.
9. Hernández-Martínez, A., et al., Oxytocin discontinuation after the active phase of induced labor: A systematic review. Women Birth, 2019. 32(2): p. 112-118.
10. Budden, A., L.J. Chen, and A. Henry, High‐dose versus low‐dose oxytocin infusion regimens for induction of labour at term. Cochrane Database Syst. Rev, 2014(10).
11. Schaider, J.J., et al., Rosen & Barkin’s 5-minute emergency medicine consult. Vol. 4. 2012: Lippincott Williams & Wilkins.
12. Kaviani, M., et al., Comparison of the Effects of Simultaneous Use of Methylergonovine and Combined Low-dose (LD) Contraceptive Pills on Hemorrhage Due to Retained Pregnancy Products after Abortion. Int. J. Curr. Microbiol. App. Sci, 2016. 5(11): p. 499-507.
13. Paris, A.E., et al., Mifepristone and misoprostol compared to osmotic dilators for cervical preparation prior to surgical abortion at 15–18 weeks’ gestation: a randomised controlled non-inferiority trial. BMJ Sex. Reprod. Health, 2020. 46(1): p. 67-72.
14. Guilbert, E.R., et al., First-trimester medical abortion practices in Canada: National survey. Can Fam Physician, 2016. 62(4): p. e201-e208.
15. Whitehouse, K., et al., Use of medications to decrease bleeding during surgical abortion: a survey of abortion providers’ practices in the United States. Contraception, 2018. 97(6): p. 500-503.
16. Jahangir, M., et al., Efficacy of vaginal Misoprostol for terminating missed abortion. KAUMS Journal (FEYZ), 2005. 9(2): p. 1-5.
17. Wewers, M.E. and N.K. Lowe, A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health, 1990. 13(4): p. 227-236.
18. Feng, X., et al., Transcutaneous acupoint electrical stimulation pain management after surgical abortion: A cohort study. Int J Surg, 2016. 30: p. 104-108.
19. Conti, J.A., et al., Self-administered lidocaine gel for pain control with first-trimester surgical abortion. Obstetrics & Gynecology, 2016. 128(2): p. 297-303.
20. Thaxton, L., et al., Nitrous Oxide Compared with Intravenous Sedation for Second-Trimester Abortion: A Randomized Controlled Trial. Obstetrics & Gynecology, 2018. 132(5): p. 1192-1197.
21. Rezvani Amin, M., et al., Correlation between visual analogue scale and short form of McGill questionnaire in patients with chronic low back pain. Qom University of Medical Sciences Journal, 2011. 5(1): p. 31-34.
22. Petca, A., et al., second trimester abortion: mifepristone plus misoprostol vs. misoprostol plus oxytocin. Farmacia, 2019. 67(5): p. 850-856.
23. Bakker, R., S. Pierce, and D. Myers, The role of prostaglandins E1 and E2, dinoprostone, and misoprostol in cervical ripening and the induction of labor: a mechanistic approach. Arch Gynecol Obstet, 2017. 296(2): p. 167-179.
24. Huffmeijer, R., et al., Salivary levels of oxytocin remain elevated for more than two hours after intranasal oxytocin administration. Neuro endocrinology letters, 2012. 33(1): p. 21-25.
25. Tehranian, A., et al., The effect of adding hyoscine to vaginal misoprostol on abortion induction success rate. Tehran Univ. Med. J, 2010. 68(4).
26. Niroumanesh, S. and N. Azadbeh, Use of vaginal Misoprostol tablets in the management of missed abortion in pregnant women. J Adv Med Biomed Res, 2002. 10(341):p 1-7.
27. Ghasemi, M., et al., Comparison of two dosing regimens of intravaginal misoporostol for second-trimester abortion. The Iranian Journal of Obstetrics, Gynecology and Infertility, 2018. 21(4): p. 19-24.
28. Sang, G.-w., et al., Termination of early pregnancy by two regimens of mifepristone with misoprostol and mifepristone with PG05—a multicentre randomized clinical trial in China. Contraception, 1994. 50(6): p. 501-510.
29. Jain, R., et al., Comparison of intramuscular methylergometrine, rectal misoprostol, and low-dose intravenousoxytocin in active management of the third stage of labor. Tzu Chi Med. J., 2019. 31(3): p. 158.
30. Tan, J., et al., Misoprostol versus ergometrine‐oxytocin for preventing postpartum haemorrhage: a systematic review and meta‐analysis of randomized controlled trials. Evid Based Med, 2016. 9(4): p. 194-204.
31. Dabbaghi Gale, T., et al., Comparison of intravenous oxytocin and oral misoprostol in reduction of postpartum hemorrhage. ZUMS Journal, 2012. 20(81): p. 1-8.
32. Whitehouse, K., et al., Effects of prophylactic oxytocin on bleeding outcomes in women undergoing dilation and evacuation: a randomized controlled trial. Obstetrics & Gynecology, 2019. 133(3): p. 484-491.
33. Huh, W.K., D. Chelmow, and F.D. Malone, A double-blinded, randomized controlled trial of oxytocin at the beginning versus the end of the third stage of labor for prevention of postpartum hemorrhage. Gynecol Obstet Invest, 2004. 58(2): p. 72-76.
34. Cunningham F. G., Norman F. G., KennethJ. L., et al. abortion. Williams obstetrics. 21th Edition. New York, MC Graw Hill.2001; pp: 855-883.
35. Fiala, C., et al., Pain during medical abortion, the impact of the regimen: a neglected issue? A review. Eur J Contracept Reprod Health Care, 2014. 19(6): p. 404-419.
36. Fiala, C., et al., Pain management for up to 9 weeks medical abortion–An international survey among abortion providers. Eur. J. Obstet. Gynecol, 2018. 225: p. 181-184.
37. Suhonen, S., et al., Pain during medical abortion: predicting factors from gynecologic history and medical staff evaluation of severity. Contraception, 2011. 83(4): p. 357-361.
38. Kemppainen, V., et al., Pain during medical abortion inearly pregnancy in teenaged and adult women. Acta Obstet Gynecol Scand, 2020.
39. Braaten, K.P., et al., A randomized comparison of intravenous sedation using a dosing algorithm compared to standard care during first-trimester surgicalabortion. Contraception, 2018. 97(6): p. 490-496.
40. Niño-Maldonado, A.I., et al., Efficacy and tolerability of intravenous methylergonovine in migraine female patients attending the emergency department: a pilot open-label study. Head Face Med, 2009. 5(1): p. 21.
Table 1. Demographic variables in drug prescription based on mean and standard deviation